{
  "company": "LUPIN",
  "report_date": "February 16, 2023",
  "filename": "LUPIN_transcript_Feb_2023.pdf",
  "quarter": "Q3",
  "fiscal_year": "2023",
  "management_team": [
    "MS. VINITA GUPTA - CEO, LUPIN LIMITED",
    "MR. NILESH GUPTA - MANAGING DIRECTOR, LUPIN LIMITED",
    "MR. RAMESH SWAMINATHAN - EXECUTIVE DIRECTOR, GLOBAL CFO AND HEAD",
    "VINITA GUPTA - CEO, LUPIN LIMITED",
    "NILESH GUPTA - MANAGING DIRECTOR, LUPIN LIMITED",
    "RAMESH SWAMINATHAN - EXECUTIVE DIRECTOR, GLOBAL CFO AND HEAD"
  ],
  "moderator": "Welcome to Lupin Limited Q3 FY23 Earnings Conference Call",
  "analysts": [],
  "qa_segments": [],
  "key_financial_metrics": {
    "sales_inr_crores": "4087",
    "growth_percentage": "3.7"
  },
  "business_highlights": [
    "acquired from Sunovion.",
    "acquired the two decent sized products.",
    "acquired assets is what I was trying to understand and you are saying that, yes, \nit had full quarter beneﬁts.",
    "acquired \nbrands and also if you can indicate what's the exposure to the US market from \nthe Mandideep facility in terms of revenues? \nVinita Gupta:  \nThe largest part of it is Suprep, Perforomist, Pennsaid and two months’ worth \nof the brands."
  ],
  "extraction_metadata": {
    "extraction_date": "2025-08-03T01:08:57.535613",
    "source_file": "data\\lupin\\LUPIN_transcript_Feb_2023.pdf",
    "text_length": 56309,
    "extraction_method": "PyMuPDF + Regex parsing + Filename analysis"
  }
}